Strategic funding Neurovalens has secured substantial funding ($28M total) and recent rounds including an £6M raise, signaling strong investor confidence and potential for partnership opportunities, grant-supported pilots, and scaled commercialization efforts in medical devices.

Sleep market expansion Modius Sleep launched October 2024 and targets chronic insomnia with a non-invasive headset, presenting a clear sales path into sleep clinics, primary care referrals, VA program integration, and payer-supported access through physician prescriptions.

Regulatory traction FDA-cleared Modius technology and industry recognition such as the 2024 SleepTech Award validate clinical credibility, enabling conversations with hospital systems, insurers, and government programs about reimbursement and large-scale adoption.

Global reach potential Headquartered in Belfast with a global health-tech focus, Neurovalens can leverage UK/EU partnerships and North American channels established through CES and NSF connections to pursue international pilots, distributors, and strategic alliances.

Clinical integration The device’s physician-prescribed model and VA program inclusion create opportunities to position Modius Sleep within sleep medicine, neurology, primary care, and veteran health networks, supported by its non-invasive, drug-free profile.